Metformin may delay diabetes onset in those at risk
NEW YORK (Reuters Health) - In people who are at risk of developing diabetes, treatment with metformin leads to modest improvements in weight, lipid (fat) profiles and fasting blood sugar. In addition, substantial reductions in insulin resistance, a condition that usually precedes diabetes, are seen, as well as the actual development of diabetes, according to a large review of published studies on this topic.
<p>You are not allowed to view links.
Register or
Login![](http://feeds.reuters.com/~a/reuters/healthNews?i=xttnVf" border="0)
</img>
</p><div class="feedflare">
You are not allowed to view links.
Register or
Login![](http://feeds.reuters.com/~f/reuters/healthNews?i=zpdXV4F" border="0)
</img>
You are not allowed to view links.
Register or
Login![](http://feeds.reuters.com/~f/reuters/healthNews?i=h8Ks8Hf" border="0)
</img>
You are not allowed to view links.
Register or
Login![](http://feeds.reuters.com/~f/reuters/healthNews?i=Ir3XLFf" border="0)
</img>
</div>
![](http://feeds.reuters.com/~r/reuters/healthNews/~4/257155137" height="1" width="1)
You are not allowed to view links.
Register or
Login
